Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ImmunoGen, Inc.
< Previous
1
2
Next >
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
December 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
November 02, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
October 27, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
September 18, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
August 28, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
July 31, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
July 27, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
July 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
May 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 09, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
May 09, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Proposed Public Offering of Common Stock
May 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
April 28, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
April 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
April 06, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
March 25, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
ImmunoGen Reports Recent Progress and 2022 Financial Results
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
Tickers
IMGN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.